Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
Authors:
- Yukihisa FujinagaYFYukihisa Fujinaga
- Hideto KawarataniHKHideto Kawaratani
- Daisuke KayaDKDaisuke Kaya
- Yuki TsujiYTYuki Tsuji
- Takahiro OzutsumiTOTakahiro Ozutsumi
- Masanori FurukawaMFMasanori Furukawa
- Koh KitagawaKKKoh Kitagawa
- Shinya SatoSSShinya Sato
- Norihisa NishimuraNNNorihisa Nishimura
- Yasuhiko SawadaYSYasuhiko Sawada
- Hiroaki TakayaHTHiroaki Takaya
- Kosuke KajiKKKosuke Kaji
Open Access
- 4 August 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (15) , 5589
Abstract
The progression of nonalcoholic steatohepatitis (NASH) is complicated. The multiple parallel-hits theory is advocated, which includes adipocytokines, insulin resistance, endotoxins, and oxidative stress. Pathways involving the gut–liver axis also mediate the progression of NASH. Angiotensin-II receptor blockers (ARB) suppress hepatic fibrosis via the activation of hepatic stellate cells (HSCs). Rifaximin, a nonabsorbable antibacterial agent, is used for the treatment of hepatic encephalopathy and has been recently reported to improve intestinal permeability. We examined the inhibitory effects on and mechanism of hepatic fibrogenesis by combining ARB and rifaximin administration. Fischer 344 rats were fed a choline-deficient/l-amino acid-defined (CDAA) diet for 8 weeks to generate the NASH model. The therapeutic effect of combining an ARB and rifaximin was evaluated along with hepatic fibrogenesis, the lipopolysaccharide–Toll-like receptor 4 (TLR4) regulatory cascade, and intestinal barrier function. ARBs had a potent inhibitory effect on hepatic fibrogenesis by suppressing HSC activation and hepatic expression of transforming growth factor-β and TLR4. Rifaximin reduced intestinal permeability by rescuing zonula occludens-1 (ZO-1) disruption induced by the CDAA diet and reduced portal endotoxin. Rifaximin directly affect to ZO-1 expression on intestinal epithelial cells. The combination of an ARB and rifaximin showed a stronger inhibitory effect compared to that conferred by a single agent. ARBs improve hepatic fibrosis by inhibiting HSCs, whereas rifaximin improves hepatic fibrosis by improving intestinal permeability through improving intestinal tight junction proteins (ZO-1). Therefore, the combination of ARBs and rifaximin may be a promising therapy for NASH fibrosis.Keywords
This publication has 44 references indexed in Scilit:
- Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier functionJournal of Hepatology, 2013
- Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis developmentInternational Journal of Molecular Medicine, 2011
- Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor ActivationThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Gut-Liver Axis and Sensing MicrobesDigestive Diseases, 2010
- Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease†Hepatology, 2009
- Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the ratBMC Research Notes, 2009
- Mechanisms of Hepatic FibrogenesisGastroenterology, 2008
- Innate immune reactivity of the liver in rats fed a cholinedeficient L-amino-acid-defined dietWorld Journal of Gastroenterology, 2008
- Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitisJournal of Hepatology, 2007
- Steatohepatitis: A tale of two “hits”?Gastroenterology, 1998